Zosano Pharma, Inc. to Present at BIO Investor Forum

FREMONT, Calif.--(Business Wire)--
Zosano Pharma, Inc., a privately held pharmaceutical company
developing a novel transdermal delivery technology for a broad range
of therapeutic indications, announced today that John Vuko, Chief
Financial Officer of Zosano will present at the 7th annual BIO
Investor Forum. Mr. Vuko will provide an update on the company's
progress. He will highlight the key features of its proprietary
transdermal delivery technology as well as the recent Phase 2 results
of its lead clinical program, the ZP-PTH rapid delivery patch for the
treatment of osteoporosis, being developed as an alternative to daily
injections.

The presentation will be delivered at the Palace Hotel in San
Francisco, Calif., on Thursday October 30th at 1:45 PM PST. A copy of
the presentation will be available on Zosano web site at
www.zosanopharma.com following the meeting.

About Zosano Pharma, Inc.

Zosano Pharma, Inc. is a privately held pharmaceutical company
developing a novel transdermal delivery technology for a broad range
of therapeutic indications. Its lead clinical program, the ZP-PTH
rapid delivery patch for the treatment of osteoporosis, is being
developed as an alternative to daily injections and has strong phase 2
study results. Zosano's transdermal delivery technology is capable of
delivering peptides, proteins, small molecules and vaccines by
permeating the skin's outer layer and ensuring significant therapeutic
effect. This proven proprietary technology offers several key
benefits, including efficacy and safety comparable to approved
injectables, needle-free delivery, a self administered patch, rapid
onset of action and room temperature storage. Zosano's transdermal
delivery technology has been clinically tested in over 400 patients
with four different peptides and a vaccine. Zosano aims to develop
products both independently and through strategic licensing and
co-development arrangements. Founded in 2006 as an ALZA Corporation
spin-out led by Nomura Phase4 Ventures, Zosano is funded by New
Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and
ProQuest Investments. For more information, please visit
www.zosanopharma.com.

Zosano Pharma, Inc.
John Vuko, CFO, 510-745-1297
jvuko@zosanopharma.com

Copyright Business Wire 2008